Why Are Lonmin Plc, Oxford BioMedica plc & Bango plc Among Today’s Biggest Gainers?

Should you buy or sell these 3 major gainers? Lonmin Plc (LON: LMI), Oxford BioMedica plc (LON: OXB) and Bango plc (LON: BGO)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in Lonmin (LSE: LMI) have soared by over 5% today after the mining company announced the appointment of a new CFO. Barrie van der Merwe will take over on 17 May and the market seems to have welcomed this prompt decision by the company following the resignation of Simon Scott.

Clearly, this is a time of major change for Lonmin as it seeks to implement an updated strategy in response to exceptionally difficult trading conditions. As part of this, it is restructuring its business and also seeking to cut costs; both of which are likely to have a positive impact on Lonmin’s bottom line over the medium to long term. And with Lonmin having the capital through which to effect its new plan following last year’s fundraising, its future seems to be brighter than it was just a handful of months ago.

This increased confidence plus a more stable commodity price environment has led to a rise in Lonmin’s share price of 99% since the turn of the year. This rapid increase could continue, although Lonmin remains a relatively high risk play and may only be of interest to less risk averse investors.

Also rising today are shares in Oxford BioMedica (LSE: OXB), with them being up over 11% despite no significant news flow having been released by the company today. In fact, the gene therapy specialist has not released an update since 7 March when it announced a new and expanded collaboration with Immune Design Corp. Since then its shares have fallen by around 6% but looking ahead, the company has clear potential to deliver profitability.

The challenge for investors, though, is that profitability may still be a long way off. And in the meantime Oxford BioMedica is in a cash burn phase which could require further fundraisings following its £8.1m placing in February. As such, and while Oxford BioMedica has a bright long term future in a very appealing space, it may only be worth a closer look for less risk averse investors.

Meanwhile, shares in mobile payments company Bango (LSE: BGO) have risen by 12% today despite a lack of news flow. Despite this, its shares have still fallen by 60% since the turn of the year even though Bango’s full-year results have showed that it is making progress. For example, it experienced significant growth in end user spend, with the company also doubling the rate of spending through the Bango payment platform. And with a stable cost base, it seems to be well-positioned to move towards profitability.

Of course, the market seems to be somewhat downbeat on Bango’s prospects judging by its recent share price fall. While today’s upward movement could indicate a change in sentiment, it may be prudent to await confirmation of this over the medium term before piling in.

Peter Stephens has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature black woman at home texting on her cell phone while sitting on the couch
Investing Articles

Could this cheap FTSE 100 stock be the next Rolls-Royce?

Paul Summers casts his eye over a battered-but-high-quality FTSE 100 stock. Is this the next top-tier company to stage a…

Read more »

ISA Individual Savings Account
Investing Articles

Hesitant over a Stocks and Shares ISA? Here’s a way to deal with scary markets

Volatile stock markets are scaring potential investors away from getting started with their first Stocks and Shares ISA in 2026.

Read more »

This way, That way, The other way - pointing in different directions
Market Movers

Standard Life’s announced a £2bn deal but its share price is largely unchanged. Why?

James Beard considers why the Standard Life share price didn’t take off today (15 April) after the group announced it…

Read more »

Happy parents playing with little kids riding in box
Investing Articles

Up 12% in a month, Hollywood Bowl is a UK dividend stock on a roll

This 5%-yielding dividend stock was one of the top performers in the FTSE 250 index today. What sent it flying…

Read more »

Close-up of children holding a planet at the beach
Investing Articles

Young investors are taking the stock market on a rollercoaster ride. Here’s how retirees can buckle up

Mark Hartley reveals the volatile impact that younger investors are having on the stock market and how UK retirees can…

Read more »

Two female adult friends walking through the city streets at Christmas. They are talking and smiling as they do some Christmas shopping.
Investing Articles

£7,500 invested in Aviva shares 5 years ago is now worth…

A lump sum pumped into Aviva shares half a decade ago has grown a lot. Andrew Mackie looks at the…

Read more »

Young female hand showing five fingers.
Investing Articles

Could £20,000 invested in these 5 dividend shares produce £14,760 of passive income over the next 10 years?

James Beard considers the potential of dividend shares to deliver amazing levels of passive income. Here are five that have…

Read more »

Workers at Whiting refinery, US
Investing Articles

At 570p, is it too late to consider buying BP shares?

Since the end of February, when the conflict in the Middle East started, BP shares have soared nearly 20%. But…

Read more »